Evidence map›Paper›PMID 18625410›Full record

ReviewPhysical medicine and rehabilitation clinics of North America2008

Current and future directions in genomics of amyotrophic lateral sclerosis.

John Ravits, Bryan J Traynor

Abstract readReview
In one paragraph

Review in Physical medicine and rehabilitation clinics of North America, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Challenges in the Understanding and Treatment of Amyotrophic Lateral Sclerosis/Motor Neuron Disease.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2015
    Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

John RavitsVirginia Mason Medical Center, 1100 Ninth Avenue, Seattle, WA 98101, USA. jravits@benaroyaresearch.org
Bryan J Traynor

Funding

Genome wide SNP analysis in Amyotrophic Lateral SclerosisZIAAG000933 · NIA · NATIONAL INSTITUTE ON AGING · PI TRAYNOR, BRYAN · 2009 to 2025
$9.8M
Microgenomic Studies of ALSR21NS051738 · NINDS · BENAROYA RESEARCH INST AT VIRGINIA MASON · PI RAVITS, JOHN · 2006 to 2007
$441k
Intramural NIH HHS ZIA AG000933NINDS NIH HHS R21 NS051738-01A1
6 · The paper itself

Abstract

New knowledge of the structure and function of the human genome and novel genomic technologies are being applied to the study of sporadic amyotrophic lateral sclerosis (ALS). These studies can examine tens to hundreds of thousands of items at once, and depend on sophisticated computer processing. Current studies are focused on genetic susceptibility and gene expression and future studies will likely focus on structural variation, gene regulation and non-protein coding regions. The hope is that they will lead to deeper understanding of molecular aspects of the disease and to rational therapeutic targets.

Indexed as

Gene ExpressionAmyotrophic Lateral SclerosisAnimalsGenetic MarkersGenetic Predisposition to DiseaseGenomicsHumansRNAGenetic MarkersRNA

Identifiers

PMID18625410
PMCPMC3524513

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.